Heydorn Arne, Bertelsen Birgitte, Nolsöe Rúna Louise Mortansdóttir, Eiken Pia, Kristensen Peter Lommer
Department of Endocrinology and Nephrology, Nordsjællands Hospital, Dyrehavevej 29, DK-3400, Hillerød, Denmark.
Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Thyroid Res. 2023 May 1;16(1):10. doi: 10.1186/s13044-023-00152-w.
Thyrotoxic periodic paralysis (TPP) is a rare condition characterized by muscle paralysis, thyrotoxicosis, and hypokalemia. It presents with paralysis of both proximal and distal musculature in upper and lower limbs and may affect respiratory musculature and the cardiac conduction system. Early diagnosis is essential, as the condition is potentially reversible by oral or intravenous potassium treatment, leading to rapid resolution without lasting weakness. Overlooking the diagnosis may result in respiratory failure and cardiac arrhythmias including QT prolongation, Torsades de points, and ventricular arrhythmias.
A 19-year-old Caucasian man was admitted acutely with paralysis in upper and lower limbs and tachycardia. Over several months, he had experienced anxiousness, sweating more than usual, had daily palpitations, shortness of breath on exertion, and loose stools, and had lost 21 kg over the last year. Initial blood gas showed very low potassium of 1.4 mM, and blood tests showed decreased Thyroid-stimulating hormone (TSH) < 0.01 × 10 IU/L, elevated free thyroxine (fT4) of 63.5 pM (reference interval (RI): 12.0-22.0 pM), and elevated total triiodothyronine (T3) of 8.2 nM (RI: 1.0-2.6 nM). He was diagnosed with TPP and treated with liquid oral potassium chloride (30 mmol every 30 minutes) and propylthiouracil (initial dose of 400 mg followed by 200 mg three times daily). TSH-receptor antibodies (TRAB) and thyroid-peroxidase antibodies (TPO-ab) were highly elevated. Thyroid ultrasound showed a normal-sized gland and color Doppler sonography showed increased vascularity throughout the gland, compatible with Graves' disease. He was discharged on day 4 with a normal potassium level and followed in the outpatient clinic where he received standard care for Graves' disease. Genetic testing using whole-genome sequencing found no genetic variants in genes previously associated with TPP.
TPP is very rare in Caucasians but more often affects young men in East Asian populations. The case presents a Caucasian man with TPP where genetic testing of CACNA1S, KCNJ18, SCN4A, KCNJ2, KCNE3, and ABCC8 shows no pathogenic variants in genes previously associated with TPP.
甲状腺毒症性周期性瘫痪(TPP)是一种罕见疾病,其特征为肌肉麻痹、甲状腺毒症和低钾血症。它表现为上肢和下肢近端及远端肌肉组织的麻痹,可能影响呼吸肌肉组织和心脏传导系统。早期诊断至关重要,因为该病症通过口服或静脉补钾治疗可能可逆,可迅速缓解且不留持久无力症状。忽视诊断可能导致呼吸衰竭和心律失常,包括QT延长、尖端扭转型室速和室性心律失常。
一名19岁的白种男性因上肢和下肢麻痹及心动过速急性入院。在数月时间里,他经历了焦虑、出汗比平时增多、每日心悸、活动时气短以及腹泻,且在过去一年体重减轻了21千克。初始血气显示血钾极低,为1.4毫摩尔/升,血液检查显示促甲状腺激素(TSH)降低<0.01×10国际单位/升,游离甲状腺素(fT4)升高至63.5皮摩尔/升(参考区间(RI):12.0 - 22.0皮摩尔/升),总三碘甲状腺原氨酸(T3)升高至8.2纳摩尔/升(RI:1.0 - 2.6纳摩尔/升)。他被诊断为TPP,并接受了液体口服氯化钾(每30分钟30毫摩尔)和丙硫氧嘧啶(初始剂量400毫克,随后每日三次,每次200毫克)治疗。促甲状腺激素受体抗体(TRAB)和甲状腺过氧化物酶抗体(TPO - ab)高度升高。甲状腺超声显示甲状腺大小正常,彩色多普勒超声显示整个腺体血管增多,符合格雷夫斯病。他在第4天血钾水平正常时出院,并在门诊接受格雷夫斯病的标准治疗。使用全基因组测序进行的基因检测未发现先前与TPP相关基因中的遗传变异。
TPP在白种人中非常罕见,但在东亚人群中更常影响年轻男性。该病例呈现了一名患有TPP的白种男性,对CACNA1S、KCNJ18、SCN4A、KCNJ2、KCNE3和ABCC8进行的基因检测显示,先前与TPP相关的基因中无致病变异。